Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PNP | P00491 | 6/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 9/20 | 0.42 |
| ▸ | POLG | P54098 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470808 | 0.92 | NT5E (0.41) | NT5EPOLBPNPHPRT1USP2 | |
| SCHEMBL27173493 | 0.87 | NT5E (0.43) | NT5EPOLBPNPHPRT1POLG | |
| SCHEMBL31244582 | 0.86 | NT5E (0.44) | NT5EPOLBPNPHPRT1POLG | |
| SCHEMBL3018983 | 0.85 | ADORA3 (0.47) | NT5EPNPUSP2TSHREDNRA | |
| SCHEMBL30716928 | 0.83 | TK1 (0.46) | PNPHPRT1USP2TSHREDNRA | |
| SCHEMBL407396 | 0.83 | NT5E (0.51) | NT5EPOLBPNPPOLG | |
| SCHEMBL26906437 | 0.81 | PNP (0.40) | NT5EPOLBPNPHPRT1 | |
| SCHEMBL29408560 | 0.81 | ADORA1 (0.59) | ADORA1 | |
| SCHEMBL5494261 | 0.81 | ADORA3 (0.46) | NT5EPNPUSP2TSHREDNRA | |
| SCHEMBL30411581 | 0.81 | NT5E (0.45) | NT5EPOLBPNPHPRT1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120077134-A | APOC 3-targeted polynucleic acid molecule and application thereof | 靖因药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-114126628-B | Compositions and methods for treating Hepatitis B Virus (HBV) infection | 维尔生物科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119654413-A | ITFG1 inhibitory nucleic acids | 莱尔纳生物制药私人有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119546629-A | Compositions and methods for treating Hepatitis Delta Virus (HDV) infection and related diseases | 维尔生物科技公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119403827-A | Compositions and methods for treating Hepatitis B Virus (HBV) infection and HBV related diseases | 维尔生物科技公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119265191-A | Hepatitis B Virus (HBV) dsRNA agent compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-119156448-A | SNCA-targeted siRNA compositions for the treatment of SNCA-related diseases | 阿尔尼拉姆医药品有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-116801886-B | LPA inhibitors and uses thereof | 成都心正合医药科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-112673103-B | Hepatitis B Virus (HBV) dsRNA agent compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-08-09 | — | — | CN | claimed |
| EP-4363580-A1 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-08 | — | — | EP | claimed |
| CN-117651768-A | Methods and compositions for treating Angiotensinogen (AGT) -related disorders | 阿尔尼拉姆医药品有限公司 | 2024-03-05 | — | — | CN | claimed |
| CN-116390943-A | Engineered hepatitis b virus neutralizing antibodies and uses thereof | 维尔生物科技有限公司 | 2023-07-04 | — | — | CN | claimed |
| CN-116261461-A | Method for stimulating cell proliferation | 新加坡科技研究局 | 2023-06-13 | — | — | CN | claimed |
| WO-2023278576-A1 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | claimed |
| CN-115461460-A | Compositions and methods for inhibiting expression of transthyretin (TTR) | 阿尔尼拉姆医药品有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-114981431-A | Methods and compositions for treating Angiotensinogen (AGT) -related disorders | 阿尔尼拉姆医药品有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-108368507-B | iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-114126628-A | Compositions and methods for treating Hepatitis B Virus (HBV) infection | 维尔生物科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | disclosed |
| CN-114126628-A | Compositions and methods for treating Hepatitis B Virus (HBV) infection | 维尔生物科技有限公司 | 2022-03-01 | — | — | CN | disclosed |